City News Live - Health

N/A

New Hope For Kidney Cancer Patients With HSA Approval Of Anticancer Drug Nexavar
August 31, 2007 08:00:00

Bayer Schering Pharma announced that the Singapore Health Sciences Authority (HSA) has approved Nexavar® (Sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (ARCC), or advanced kidney cancer. [click link for full article] -�[Read�more]

N/A

Vital Options International, ASTRO Partner To Raise Awareness Of Cancer Survivorship, USA
August 31, 2007 08:00:00

As part of its continued effort to give back to the cancer communities in the cities visited during its annual scientific meeting, the Fairfax, Virginia-based American Society for Therapeutic Radiology and Oncology (ASTRO) is partnering with Vital Options International to raise awareness of cancer survivorship. Vital Options International is a not-for-profit cancer communications, support and advocacy organization with a mission to facilitate a global cancer dialogue. [click link for full article] -�[Read�more]

N/A

Finding Better Ways To Diagnose Pancreatic Cancer And Chronic Pancreatitis
August 31, 2007 07:00:00

In the August issue of Molecular & Cellular Proteomics (http://www.mcponline.org), scientists provide the first large scale identification of proteins that are overexpressed in chronic pancreatitis, an inflammatory condition of the pancreas that shares many features with pancreatic cancer. The information will help diagnose the early stages of both diseases. [click link for full article] -�[Read�more]

N/A

Gene Signature Spells Poor Outcome
August 31, 2007 07:00:00

Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones. [click link for full article] -�[Read�more]

N/A

Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation And Self
August 31, 2007 07:00:00

Novocell Inc., a stem cell engineering company, announced research findings that for the first time identify two prominent cancer cell signaling pathways as essential for the efficient proliferation and self-renewal of human embryonic stem cells (hESCs). The findings were prepublished online August 29, 2007 in Blood First Edition Paper titled "Self-Renewal of Human Embryonic Stem Cells Requires Insulin-like Growth Factor-1 Receptor and ERBB2 Receptor Signaling. [click link for full article] -�[Read�more]

N/A

YM BioSciences USA Cleared By US FDA To Initiate Phase II Clinical Trial Of Nimotuzumab In Children
August 31, 2007 07:00:00

YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. [click link for full article] -�[Read�more]

N/A

A Worldwide Phase III Clinical Trial Seeks U.S. Patients To Explore Investigational Drug Phenoxodiol
August 31, 2007 07:00:00

A new website has been launched to facilitate recruitment of patients to OVATURE (OVArian TUmor REsponse), a Phase III clinical trial of an investigational ovarian cancer drug phenoxodiol. The goal of http://www.OVATUREtrial.com is to inform ovarian cancer patients about the OVATURE trial, which is actively recruiting patients, and to provide more information about the trial and the investigational drug phenoxodiol. [click link for full article] -�[Read�more]

N/A

Integrins and cancer
August 31, 2007 00:02:53

Integrins play an important physiologic role in cell adhesion, and accumulating evidence suggests that they also regulate cell growth, proliferation, migration, and apoptosis. A number of congenital and acquired disease states have been associated with integrins, and small- molecule integrin inhibitors have been approved for treatment of benign hematologic diseases. In cancer, aberrant expression with normal functioning rather than dominant genetic variations of genes coding for integrins has generally been observed. This aberrant expression is mediated through "bidirectional" receptor signaling and interaction with corresponding signals from growth factor signaling pathways, leading to inhibition of apoptosis, induction of cell proliferation, extracellular matrix remodeling, migration, and angiogenesis. From a clinical perspective, a growing number of molecules targeting integrins have been developed for treatment and imaging purposes; clinical studies in melanoma, prostate cancer, and other malignancies are underway. This review summarizes the biology of integrins, the signal transduction pathways they regulate, and their role in different stages of carcinogenesis. Furthermore, it provides a synopsis on the clinical advancements in integrin targeting for therapeutic and imaging purposes in cancer. (Source: CancerNetwork) -�[Read�more]

N/A

The biology of integrins
August 31, 2007 00:02:53

Adhesion molecules have traditionally been thought of simply as receptors that permit anchorage to other cells or to the underlying extracellular matrix (ECM). However, within the past decade it has become apparent that adhesion molecules such as integrins mediate critical cytosolic signaling events that have a dramatic impact upon cell proliferation, survival, and motility. Integrins act to regulate both physiologic and pathologic events, including complex processes such as angiogenesis, tumor growth, and metastasis. For these reasons, integrins have become attractive targets for drug development, and several effective integrin antagonists are now under clinical evaluation. In turn, the use of integrin-targeted reagents has provided additional mechanistic insights into the workings of the receptor. In particular, it has become apparent that integrins are "mechanosensory" receptors that operate in a context-dependent manner. While integrins that ligate substrate-immobilized ligands typically transduce positive signals into the cell, antagonized or unligated integrins promote negative signaling into the cell, leading to cell cycle arrest or apoptosis. Thus, integrins appear to fulfill a biosensor function, wherein they constantly interrogate the local ECM, and modulate cell behavior accordingly. These new roles that integrins play reinforce the choice of integrins as a therapeutic target, even as they lead us to reassess and optimize current clinical strategies. (Source: CancerNetwork) -�[Read�more]

N/A

Integrins in cancer: novel therapeutic approaches
August 31, 2007 00:02:53

The integrins are a family of transmembrane receptors important for the cell-cell and cell-matrix interactions that relate to processes of cell adhesion, migration, invasion, angiogenesis, and survival. (Source: CancerNetwork) -�[Read�more]

N/A	Diagnostic dilemma: gi disease August 31, 2007 00:02:53 A 72-year-old man is referred for evaluation of abnormal liver chemistries. He has a history of unresectable pancreatic cancer (adenocarcinoma of the head). (Source: CancerNetwork) -�[Read�more]

N/A

Th vs tch in metastatic breast cancer: take your pick
August 31, 2007 00:02:53

In the first overall survival analysis of the BCIRG 007 study in metastatic breast cancer, the addition of carboplatin to a docetaxel (Taxotere)/trastuzumab (Herceptin) regimen did not improve overall survival. (Source: CancerNetwork) -�[Read�more]

N/A

Antibody-drug conjugate represents a new direction for treatment of her2-positive breast cancer pati
August 31, 2007 00:02:53

A first-in-class HER2 antibody-drug conjugate may represent an effective new strategy in breast cancer therapy, according to phase I data (Source: CancerNetwork) -�[Read�more]

N/A	Sun safety program for younger kids gets shining results August 31, 2007 00:02:53 A nurse-run program for Florida school children has been tremendously successful in teaching them how to protect their skin when in the sun (Source: CancerNetwork) -�[Read�more]

N/A

Acs studies link patients insurance status to cancer outcomes
August 31, 2007 00:02:53

Previous studies have shown that uninsured adults or those in public programs are less likely to receive preventive cancer care. Two new studies from American Cancer Society (ACS) researchers have found that people who were uninsured or enrolled in Medicaid were more likely to present with late-stage cancer than those with private medical insurance (Source: CancerNetwork) -�[Read�more]

N/A

Phase iii failure rates in oncology drugs unacceptable
August 31, 2007 00:02:53

These are exciting times in oncology. Over the past 2 decades, we have made remarkable progress in our understanding of the molecular and cellular processes involved in cancer progression. (Source: CancerNetwork) -�[Read�more]

N/A	value meal dosing of lapatinib is proposed August 31, 2007 00:02:53 Specifically, they looked at lapatinib (Tykerb), which was FDA approved last March for use in patients with metastatic HER2-positive breast cancer in combination with capecitabine (Xeloda). (Source: CancerNetwork) -�[Read�more]

N/A	Avoiding copay shock August 31, 2007 00:02:53 Studies have found that most oncologists rarely discuss the financial implications of cancer treatments with their patients. (Source: CancerNetwork) -�[Read�more]

N/A	Rt plus local paclitaxel gel promising in esophageal ca August 31, 2007 00:02:53 Paclitaxel injected directly into esophageal tumors in conjunction with radiotherapy (RT) proved safe and technically feasible in a small phase IIa, dose-escalation trial (Source: CancerNetwork) -�[Read�more]

N/A	Colon cancer trial of vectibix is recruiting August 31, 2007 00:02:53 Amgen is currently enrolling patients in a phase III study designed to evaluate the effectiveness of panitumumab (Vectibix) in combination with chemotherapy (FOLFIRI) (Source: CancerNetwork) -�[Read�more]

Cancer News

RSS Feeds

Links Sort by: PageRank | Date | Hits | Alphabetical